Mouwasat Medical Services Valuation
Is 4002 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4002 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4002 (SAR87.6) is trading above our estimate of fair value (SAR74.45)
Significantly Below Fair Value: 4002 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4002?
Key metric: As 4002 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4002's PE Ratio? | |
|---|---|
| PE Ratio | 26.6x |
| Earnings | ر.س658.09m |
| Market Cap | ر.س17.52b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.3x |
| Enterprise Value/EBITDA | 18.7x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does 4002's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 36x | ||
4017 Dr. Soliman Abdel Kader Fakeeh Hospital | 54.7x | 19.1% | ر.س15.7b |
4004 Dallah Healthcare | 31.5x | 14.9% | ر.س14.8b |
4005 National Medical Care | 26.9x | 11.2% | ر.س7.4b |
4009 Middle East Healthcare | 30.7x | 21.5% | ر.س6.5b |
4002 Mouwasat Medical Services | 26.6x | 16.4% | ر.س17.5b |
Price-To-Earnings vs Peers: 4002 is good value based on its Price-To-Earnings Ratio (26.6x) compared to the peer average (36x).
Price to Earnings Ratio vs Industry
How does 4002's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 4002 is expensive based on its Price-To-Earnings Ratio (26.6x) compared to the Asian Healthcare industry average (20.9x).
Price to Earnings Ratio vs Fair Ratio
What is 4002's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 26.6x |
| Fair PE Ratio | 32.7x |
Price-To-Earnings vs Fair Ratio: 4002 is good value based on its Price-To-Earnings Ratio (26.6x) compared to the estimated Fair Price-To-Earnings Ratio (32.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س87.60 | ر.س119.65 +36.6% | 11.7% | ر.س145.00 | ر.س92.30 | n/a | 14 |
| Dec ’25 | ر.س91.00 | ر.س123.29 +35.5% | 10.5% | ر.س145.00 | ر.س92.30 | n/a | 14 |
| Nov ’25 | ر.س94.10 | ر.س123.72 +31.5% | 10.8% | ر.س145.00 | ر.س90.80 | n/a | 12 |
| Oct ’25 | ر.س100.00 | ر.س124.33 +24.3% | 10.9% | ر.س145.00 | ر.س90.20 | n/a | 12 |
| Sep ’25 | ر.س106.20 | ر.س125.75 +18.4% | 12.2% | ر.س152.00 | ر.س90.20 | n/a | 12 |
| Aug ’25 | ر.س117.00 | ر.س132.52 +13.3% | 10.6% | ر.س152.00 | ر.س96.90 | n/a | 11 |
| Jul ’25 | ر.س120.00 | ر.س128.39 +7.0% | 12.7% | ر.س152.00 | ر.س96.90 | n/a | 12 |
| Jun ’25 | ر.س107.00 | ر.س127.48 +19.1% | 11.9% | ر.س146.00 | ر.س96.90 | n/a | 12 |
| May ’25 | ر.س134.00 | ر.س126.38 -5.7% | 12.4% | ر.س146.00 | ر.س96.90 | n/a | 13 |
| Apr ’25 | ر.س136.80 | ر.س120.50 -11.9% | 14.7% | ر.س146.00 | ر.س74.40 | n/a | 13 |
| Mar ’25 | ر.س123.40 | ر.س119.31 -3.3% | 14.7% | ر.س145.00 | ر.س71.30 | n/a | 12 |
| Feb ’25 | ر.س120.20 | ر.س117.06 -2.6% | 14.8% | ر.س145.00 | ر.س71.30 | n/a | 12 |
| Jan ’25 | ر.س114.80 | ر.س113.99 -0.7% | 13.5% | ر.س132.50 | ر.س71.30 | n/a | 12 |
| Dec ’24 | ر.س112.60 | ر.س112.31 -0.3% | 13.0% | ر.س132.50 | ر.س71.30 | ر.س91.00 | 11 |
| Nov ’24 | ر.س98.00 | ر.س111.98 +14.3% | 13.6% | ر.س132.50 | ر.س68.70 | ر.س94.10 | 11 |
| Oct ’24 | ر.س106.00 | ر.س113.05 +6.7% | 13.0% | ر.س132.50 | ر.س71.00 | ر.س100.00 | 11 |
| Sep ’24 | ر.س110.20 | ر.س114.87 +4.2% | 13.4% | ر.س132.50 | ر.س71.00 | ر.س106.20 | 11 |
| Aug ’24 | ر.س126.50 | ر.س114.60 -9.4% | 13.4% | ر.س132.50 | ر.س72.50 | ر.س117.00 | 10 |
| Jul ’24 | n/a | ر.س114.60 0% | 13.4% | ر.س132.50 | ر.س72.50 | ر.س120.00 | 10 |
| Jun ’24 | ر.س111.00 | ر.س112.11 +1.0% | 13.3% | ر.س130.00 | ر.س72.50 | ر.س107.00 | 9 |
| May ’24 | ر.س125.60 | ر.س113.40 -9.7% | 15.7% | ر.س135.00 | ر.س65.00 | ر.س134.00 | 10 |
| Apr ’24 | ر.س117.50 | ر.س111.56 -5.1% | 16.2% | ر.س135.00 | ر.س64.50 | ر.س136.80 | 9 |
| Mar ’24 | ر.س92.00 | ر.س108.56 +18.0% | 19.3% | ر.س135.00 | ر.س54.00 | ر.س123.40 | 9 |
| Feb ’24 | ر.س103.80 | ر.س108.15 +4.2% | 18.4% | ر.س135.00 | ر.س54.00 | ر.س120.20 | 10 |
| Jan ’24 | ر.س104.50 | ر.س109.78 +5.1% | 21.1% | ر.س141.05 | ر.س54.00 | ر.س114.80 | 9 |
| Dec ’23 | ر.س96.50 | ر.س111.67 +15.7% | 21.9% | ر.س141.05 | ر.س54.00 | ر.س112.60 | 9 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:40 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mouwasat Medical Services Company is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jassim Al-Jubran | Aljazira Capital Company |
| Rim Ben Salah Gharbi | AlphaMena |
| Kais Kriaa | AlphaMena |